Table 2 MDS vaccines in ongoing trials
From: Vaccines: a promising therapy for myelodysplastic syndrome
Vaccine | Payload | Phase | NCT | MDS Indication | Product(s) |
|---|---|---|---|---|---|
Dendritic cell vaccine [119] | WT-1 | I/II | NCT03083054 | HR-MDS | WT-1 mRNA electroporated in autologous DCs |
Peptide vaccine [120] | IL-3 | I | NCT03113643 | HR-MDS | Diphtheria toxin linked with IL-3+ AZA or AZA/venetoclax |
Dendritic cell vaccine [121] | Whole cell | I | NCT04999943 | Elderly (> 60 years) MDS | DC vaccine+ HMA |